Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant gram-positive bacteria

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 4, 2007, Pages 557-571

  Decousser, Jean Winoc ^a   Bourgeois Nicolaos, Nadege ^b   Doucet Populaire, Florence ^c  

^a Centre Hospitalier de Dourdan   (France)

^b BICHAT HOSPITAL   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Dalbavancin; Gram positive bacteria; Lipoglycopeptide; Multidrug resistant

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEFTOBIPROLE; CEFTRIAXONE; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; LONG ACTING DRUG; ORITAVANCIN; OXACILLIN; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TAZOBACTAM; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABNORMAL LABORATORY RESULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CATHETER INFECTION; CLINICAL TRIAL; COLONY FORMING UNIT; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS; FEVER; GRAM POSITIVE BACTERIUM; HEARING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; KIDNEY DISEASE; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; THRUSH; UNSPECIFIED SIDE EFFECT; VESTIBULAR FUNCTION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STREPTOCOCCUS; TEICOPLANIN;

EID: 34547899185     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.4.557     Document Type: Article

References (47)

1. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. 71, 968-980 (2006).
2. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55(Suppl. S2), ii15-ii20 (2005).
3. Jones RN, Streit JM, Fritsche TR. Validation of commercial dry-form microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int. J. Antimicrob. Agents 23, 197-199 (2004).
4. Mushtaq S, Warner M, Johnson AP et al. Activity of dalbavancin against staphylococci and streptococci assessed by BSAC and NCCLS agar dilution methods. J. Antimicrob. Chemother. 54, 617-620 (2004).
5. Fritsche TR, Rennie RB, Goldstein BP et al. Comparison of dalbavancin MIC values determined by Etest (AB Biodisk) and reference dilution methods using Grain-positive organisms. J. Clin. Microbiol. 44, 2988-2990 (2006).
6. Biedenbach DJ, Ross JE, Fritsche TR et al. Activity of dalbavancin against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 45, 998-1004 (2007).
7. Jones RN, Sader HS, Fritsche TR et al. Selection of a surrogate agent (vancomycin or reicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. 44, 2622-2625 (2006).
8. Lopez S, Hackbarth C, Romano G et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother. 55(Suppl. S2), ii21-ii24 (2005).
9. Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48, 137-143 (2004).
10. Jones RN, Stiwell MG, Sailer HS et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States surveillance program. Diagn. Microbiol. Infect. Dis. 54, 149-153 (2006).
11. Streit JM, Sailer HS, Fritsche TR et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol, Infect. Dis. 53, 307-310 (2005).
12. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. 11, 95-100 (2005).
13. Lin G, Credito K, Ednie LM et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49, 770-772 (2005).
14. Goldstein EJC, Citron DM, Merriam CV et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob. Agents Chemother. 47, 1968-1971 (2003).
15. Goldstein EJC, Citron DM, Warren YA et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother. 50, 2875-2879 (2006).
16. Lin G, Smith K, Ednie LM et al. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob. Agents Chemother. 49, 5182-5184 (2005).
17. Goldstein BP, Draghi DC, Sheehan DJ et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob. Agents Chemother. 51, 1150-1154 (2007).
18. Bowker KE, Noel AR, MacGowan AR Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J. Antimicrob. Chemother. 58, 802-805. (2006).
19. Bozdogan B, Esel D, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52, 864-868 (2003).
20. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother. 58, 627-631 (2006).
21. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37, 1298-1303 (2003).
22. Johnson DM, Fritsche TR, Sader HS et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents 27, 557-560 (2006).
23. Denis O, Nonhoff C, Deplano A et al. In vitro activity of ceftobiprole, dalbavancin and tigecycline against methicillin-resistant Staphylococcus aureus strains from hospitalised patients in Belgium. Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Disease. Munich, Germany, Abstract P784 (2007).
24. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50, 1581-1585 (2006).
25. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 1079-1082 (2006).
26. Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother. 55(Suppl. S2), ii25-ii30 (2005).
27. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 51, 1633-1642 (2007).
28. Jabes D, Candiani G, Romano G et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother. 48, 1118-1123 (2004).
29. Lefort A, Pavie J, Garry L et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother. 48, 1061-1064 (2004).
30. Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect. 50, 206-209 (2005).
31. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J. Clin. Pharmacol. 45, 1279-1287 (2005).
32. Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48, 940-945 (2004).
33. Solon EG, Dowell JA, Lee J et al. Distribution of radioactivity in bone and related structures following administration of [14C]-dalbavancin to New Zealand white rabbits. Antimicrob. Agents Chemother. doi:10.1128/AAC.00020-07 (2007) (Epub ahead of print).
34. Raad I, Darouiche R, Vasquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. 40, 374-380 (2005).
35. Goldstein BP, Jones RN, Fritsche TR et al. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn. Microbiol. Infect. Dis. 54, 83-87 (2006).
36. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41, 1407-1415 (2005).
37. Carmeli T. Rothermel C, Sheehan D et al. Analysis of patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in a phase 3 study of dalbavancin vs. linezolid for the treatment of complicated skin and soft tissue infections (CSSTI). 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27-30 September (2006).
38. Campbell KC, Kelly E, Targovnik N et al. Audiologic monitoring for potential ototoxicicty in a phase I clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol. 14, 157-168 (2003).
39. Lye D, Athan E, O'Brien D. Teicoplanin hypersensitivity syndrome. Int. J. Antimicrob. Agents 29(4), 476-478 (2007).
40. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44, 3883-3886 (2006).
41. Tenover FC, Moellering RC. The rationale for revising the CLSI vancomycin minimal inhibitory concentration interpretative criteria for Staphylococcus aureus. Clin. Infect. Dis. 44, 1208-1215 (2007).
42. Wooton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45, 329-332 (2007).
43. Ruhe JJ, Smith N, Bradsher RW et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin. Infect. Dis. 44, 777-784 (2007).
44. Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44, 785-787 (2007).
45. Ellis MW, Lewis JS. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis. 18, 496-501 (2005).
46. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130, 947-955 (2006).
47. Dumitrescu O, Boisset S, Badiou C et al. Effects of antibiotics on S. aureus producing Panton-Valentine leukocidin. Antimicrob. Agents Chemother. 51, 1515-1519 (2007).